• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Market characteristics o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five Forces Summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Product o Market segments o Comparison by Product o mAbs - Market size and forecast 2019-2024 o Human insulin - Market size and forecast 2019-2024 o Erythropoeitin - Market size and forecast 2019-2024 o Clotting factors - Market size and forecast 2019-2024 o Others - Market size and forecast 2019-2024 o Market opportunity by Product • Market segmentation by Therapy Area o Market segments o Metabolic and endocrine disorders o Hematopoiesis o Fertility o Cancer o Autoimmune diseases o Infectious diseases o Protein vaccine • Market segmentation by Protein Function o Market segments o Enzymatic and regulatory activity o Special targeting activity o Vaccines o Protein diagnostics • Customer Landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o APAC - Market size and forecast 2019-2024 o South America - Market size and forecast 2019-2024 o MEA - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography o Market drivers o Market challenges o Market trends • Vendor Landscape o Overview o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o AbbVie Inc. o Amgen Inc. o AstraZeneca Plc o Eli Lilly and Co. o F. Hoffmann-La Roche Ltd. o Johnson & Johnson o Merck & Co. Inc. o Novo Nordisk AS o Pfizer Inc. o Sanofi • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2019 - 2024 ($ billion) • 13: Global market: Year-over-year growth 2019 - 2024 (%) • 14: Five forces analysis 2019 & 2024 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2019 • 21: Product - Market share 2019-2024 (%) • 22: Comparison by Product • 23: mAbs - Market size and forecast 2019-2024 ($ billion) • 24: mAbs - Year-over-year growth 2019-2024 (%) • 25: Human insulin - Market size and forecast 2019-2024 ($ billion) • 26: Human insulin - Year-over-year growth 2019-2024 (%) • 27: Erythropoeitin - Market size and forecast 2019-2024 ($ billion) • 28: Erythropoeitin - Year-over-year growth 2019-2024 (%) • 29: Clotting factors - Market size and forecast 2019-2024 ($ billion) • 30: Clotting factors - Year-over-year growth 2019-2024 (%) • 31: Others - Market size and forecast 2019-2024 ($ billion) • 32: Others - Year-over-year growth 2019-2024 (%) • 33: Market opportunity by Product • 34: Customer landscape • 35: Market share by geography 2019-2024 (%) • 36: Geographic comparison • 37: North America - Market size and forecast 2019-2024 ($ billion) • 38: North America - Year-over-year growth 2019-2024 (%) • 39: Europe - Market size and forecast 2019-2024 ($ billion) • 40: Europe - Year-over-year growth 2019-2024 (%) • 41: APAC - Market size and forecast 2019-2024 ($ billion) • 42: APAC - Year-over-year growth 2019-2024 (%) • 43: South America - Market size and forecast 2019-2024 ($ billion) • 44: South America - Year-over-year growth 2019-2024 (%) • 45: MEA - Market size and forecast 2019-2024 ($ billion) • 46: MEA - Year-over-year growth 2019-2024 (%) • 47: Key leading countries • 48: Market opportunity by geography ($ billion) • 49: Impact of drivers and challenges • 50: Vendor landscape • 51: Landscape disruption • 52: Industry risks • 53: Vendors covered • 54: Market positioning of vendors • 55: AbbVie Inc. - Overview • 56: AbbVie Inc. - Business segments • 57: AbbVie Inc. - Key offerings • 58: AbbVie Inc. - Key customers • 59: AbbVie Inc. - Segment focus • 60: Amgen Inc. - Overview • 61: Amgen Inc. - Business segments • 62: Amgen Inc. - Key offerings • 63: Amgen Inc. - Key customers • 64: Amgen Inc. - Segment focus • 65: AstraZeneca Plc - Overview • 66: AstraZeneca Plc - Business segments • 67: AstraZeneca Plc - Key offerings • 68: AstraZeneca Plc - Key customers • 69: AstraZeneca Plc - Segment focus • 70: Eli Lilly and Co. - Overview • 71: Eli Lilly and Co. - Business segments • 72: Eli Lilly and Co. - Key offerings • 73: Eli Lilly and Co. - Key customers • 74: Eli Lilly and Co. - Segment focus • 75: F. Hoffmann-La Roche Ltd. - Overview • 76: F. Hoffmann-La Roche Ltd. - Business segments • 77: F. Hoffmann-La Roche Ltd. - Key offerings • 78: F. Hoffmann-La Roche Ltd. - Key customers • 79: F. Hoffmann-La Roche Ltd. - Segment focus • 80: Johnson & Johnson - Overview • 81: Johnson & Johnson - Business segments • 82: Johnson & Johnson - Key offerings • 83: Johnson & Johnson - Key customers • 84: Johnson & Johnson - Segment focus • 85: Merck & Co. Inc. - Overview • 86: Merck & Co. Inc. - Business segments • 87: Merck & Co. Inc. - Key offerings • 88: Merck & Co. Inc. - Key customers • 89: Merck & Co. Inc. - Segment focus • 90: Novo Nordisk AS - Overview • 91: Novo Nordisk AS - Business segments • 92: Novo Nordisk AS - Key offerings • 93: Novo Nordisk AS - Key customers • 94: Novo Nordisk AS - Segment focus • 95: Pfizer Inc. - Overview • 96: Pfizer Inc. - Business segments • 97: Pfizer Inc. - Key offerings • 98: Pfizer Inc. - Key customers • 99: Pfizer Inc. - Segment focus • 100: Sanofi - Overview • 101: Sanofi - Business segments • 102: Sanofi - Key offerings • 103: Sanofi - Key customers • 104: Sanofi - Segment focus • 105: Currency conversion rates for US$ • 106: Research Methodology • 107: Validation techniques employed for market sizing • 108: Information sources • 109: List of abbreviations

AbbVie Inc., Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Novo Nordisk AS, Pfizer Inc., Sanofi